- Report
- September 2025
- 96 Pages
Germany
From €4249EUR$4,500USD£3,547GBP
- Book
- September 2025
- 488 Pages
From €378EUR$400USD£315GBP
- Report
- August 2025
- 205 Pages
Global
From €4674EUR$4,950USD£3,902GBP
- Report
- June 2025
- 80 Pages
From €3258EUR$3,450USD£2,719GBP
- Report
- May 2025
- 191 Pages
Global
From €4674EUR$4,950USD£3,902GBP
- Report
- May 2025
- 102 Pages
Global
From €2785EUR$2,950USD£2,325GBP
- Report
- May 2025
- 80 Pages
Middle East, Africa
From €2785EUR$2,950USD£2,325GBP
- Report
- May 2025
- 80 Pages
From €2785EUR$2,950USD£2,325GBP
- Report
- May 2025
- 95 Pages
Asia Pacific
From €3258EUR$3,450USD£2,719GBP
- Report
- May 2025
- 96 Pages
Europe
From €3258EUR$3,450USD£2,719GBP
- Report
- May 2025
- 87 Pages
North America
From €2785EUR$2,950USD£2,325GBP
- Report
- May 2025
- 170 Pages
Global
From €4391EUR$4,650USD£3,665GBP
- Report
- April 2025
- 162 Pages
Global
From €4391EUR$4,650USD£3,665GBP
- Report
- April 2025
- 145 Pages
Global
From €4580EUR$4,850USD£3,823GBP
- Report
- March 2025
- 219 Pages
Global
From €4391EUR$4,650USD£3,665GBP
- Report
- October 2024
- 202 Pages
Global
From €2313EUR$2,450USD£1,931GBP
- Report
- September 2024
- 115 Pages
Global
From €4249EUR$4,500USD£3,547GBP
- Report
- August 2024
- 163 Pages
Global
From €2823EUR$2,990USD£2,357GBP
- Report
- March 2024
- 118 Pages
Global
From €4249EUR$4,500USD£3,547GBP
- Report
- March 2024
- 221 Pages
Global
From €2313EUR$2,450USD£1,931GBP

The Biosimilar market is a subset of the biotechnology industry that focuses on the development and production of biologic drugs that are similar to existing biologic drugs. Biosimilars are created using a process called recombinant DNA technology, which involves the manipulation of genetic material to create a drug that is similar to an existing biologic drug. Biosimilars are typically used to treat chronic conditions such as cancer, rheumatoid arthritis, and multiple sclerosis. Biosimilars are typically cheaper than their brand-name counterparts, making them an attractive option for patients and healthcare providers.
Some companies in the Biosimilar market include Amgen, Biocon, Celltrion, Dr. Reddy's Laboratories, Mylan, Pfizer, Sandoz, and Teva Pharmaceuticals. Show Less Read more